Overview

Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to demonstrate safety and efficacy of DE-114 ophthalmic solution compared to its Placebo and Olopatadine hydrochloride 0.1% ophthalmic solution in patients with allergic conjunctivitis.
Phase:
Phase 3
Details
Lead Sponsor:
Santen Pharmaceutical Co., Ltd.
Treatments:
Epinastine
Olopatadine Hydrochloride
Ophthalmic Solutions
Pharmaceutical Solutions